Research Grade Bemarituzumab
Bemarituzumab (bema), afirst-in-classhumanizedIgG1monoclonalantibody, selectivelybindsto2bIsoformofthefibroblastgrowthfactorreceptor (FGFR2b) .Bemarituzumab (FPA144) isafirst-in-classhumanizedimmunoglobulinG1monoclonalantibodyspecifictothesplice-variantFGFR2bthatinhibitsbindingoftheligandsFGF7, FGF10, andFGF22.Specifically, bemarituzumabdoesnotinhibitbindingofFGF23, theligandresponsibleforphosphateandvitaminDmetabolism, therebypotentiallyavoidingtheriskofhyperphosphatemiaassociatedwithpan-FGFRtyrosinekinaseinhibitors.BemarituzumabisalsoglycoengineeredforincreasedaffinityforthehumanFcgammaRIIIAreceptorexpressedonnaturalkillercells, enablingenhancedantibody-dependentcellmediatedcytotoxicity.
Product Specifications
Product Name Alternative
FPA144, FPA-144, FPA114-A, CAS:1952272-74-0
Expression System
Mammalian Cells
Host
Humanized
Target
K-sam, KSAM, CD332, Keratinocytegrowthfactorreceptor, Fibroblastgrowthfactorreceptor2, FGFR-2, FGFR2, KGFR, BEK
Clonality
Monoclonal
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Purification
Protein A/G purified from cell culture supernatant.
Concentration
1 mg/mL
Purity
> 95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH7.4.
Storage Conditions
Notes
For research use only. Not suitable for clinical or therapeutic use.
Species
Human
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
